Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Jan 20

PMID 33466444

Citations 15

Authors

Ana Rita Franco

Francesco Peri

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is an infectious disease caused by (Mtb) that sits in the top 10 leading causes of death in the world today and is the current leading cause of death among infectious diseases. Although there is a licensed vaccine against TB, the bacilli Calmette-Guérin (BCG) vaccine, it has several limitations, namely its high variability of efficacy in the population and low protection against pulmonary tuberculosis. New vaccines for TB are needed. The World Health Organization (WHO) considers the development and implementation of new TB vaccines to be a priority. Subunit vaccines are promising candidates since they can overcome safety concerns and optimize antigen targeting. Nevertheless, these vaccines need adjuvants in their formulation in order to increase immunogenicity, decrease the needed antigen dose, ensure a targeted delivery and optimize the antigens delivery and interaction with the immune cells. This review aims to focus on adjuvants being used in new formulations of TB vaccines, namely candidates already in clinical trials and others in preclinical development. Although no correlates of protection are defined, most research lines in the field of TB vaccination focus on T-helper 1 (Th1) type of response, namely polyfunctional CD4+ cells expressing simultaneously IFN-γ, TNF-α, and IL-2 cytokines, and also Th17 responses. Accordingly, most of the adjuvants reviewed here are able to promote such responses. In the future, it might be advantageous to consider a wider array of immune parameters to better understand the role of adjuvants in TB immunity and establish correlates of protection.

Citing Articles

Lipid Antigens: Revealing the Hidden Players in Adaptive Immune Responses.

Eskandari T, Eivazzadeh Y, Khaleghinia F, Kashi F, Oksenych V, Haghmorad D Biomolecules. 2025; 15(1).

PMID: 39858478 PMC: 11763959. DOI: 10.3390/biom15010084.

Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.

Jung M, Kim H, Choi E, Shin M, Shin S Hum Vaccin Immunother. 2024; 20(1):2317439.

PMID: 39693178 PMC: 10913723. DOI: 10.1080/21645515.2024.2317439.

Systematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists.

Riel A, Rungelrath V, Elwaie T, Rasheed O, Hicks L, Ettenger G Int J Mol Sci. 2024; 25(18).

PMID: 39337517 PMC: 11432005. DOI: 10.3390/ijms251810031.

Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.

Wang H, Wang S, Fang R, Li X, Xing J, Li Z Vaccines (Basel). 2024; 12(1).

PMID: 38250851 PMC: 10820143. DOI: 10.3390/vaccines12010038.

Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.

Gyu Choi H, Kwon K, Shin S Vaccine X. 2023; 15:100400.

PMID: 37965276 PMC: 10641539. DOI: 10.1016/j.jvacx.2023.100400.

References

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S . Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine. 2017; 35(12):1652-1661. DOI: 10.1016/j.vaccine.2017.01.055. View

Sable S, Posey J, Scriba T . Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clin Microbiol Rev. 2019; 33(1). PMC: 6822991. DOI: 10.1128/CMR.00100-19. View

Coler R, Day T, Ellis R, Piazza F, Beckmann A, Vergara J . The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018; 3:34. PMC: 6123489. DOI: 10.1038/s41541-018-0057-5. View

Cauwelaert N, Desbien A, Hudson T, Pine S, Reed S, Coler R . The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. PLoS One. 2016; 11(1):e0146372. PMC: 4701231. DOI: 10.1371/journal.pone.0146372. View

Bastola R, Noh G, Keum T, Bashyal S, Seo J, Choi J . Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res. 2017; 40(11):1238-1248. DOI: 10.1007/s12272-017-0969-z. View

Poecheim J, Barnier-Quer C, Collin N, Borchard G . Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses. Vaccines (Basel). 2016; 4(3). PMC: 5041026. DOI: 10.3390/vaccines4030032. View

Gillard P, Yang P, Danilovits M, Su W, Cheng S, Pehme L . Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study. Tuberculosis (Edinb). 2016; 100:118-127. DOI: 10.1016/j.tube.2016.07.005. View

Hellfritzsch M, Scherliess R . Mucosal Vaccination via the Respiratory Tract. Pharmaceutics. 2019; 11(8). PMC: 6723941. DOI: 10.3390/pharmaceutics11080375. View

Yu W, Hu T . Conjugation with an Inulin-Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein. Mol Pharm. 2016; 13(11):3626-3635. DOI: 10.1021/acs.molpharmaceut.6b00138. View

10.

Dedloff M, Effler C, Holban A, Gestal M . Use of Biopolymers in Mucosally-Administered Vaccinations for Respiratory Disease. Materials (Basel). 2019; 12(15). PMC: 6695719. DOI: 10.3390/ma12152445. View

11.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

12.

Woodworth J, Cohen S, Moguche A, Plumlee C, Agger E, Urdahl K . Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung. Mucosal Immunol. 2016; 10(2):555-564. PMC: 5325828. DOI: 10.1038/mi.2016.70. View

13.

Lewinsohn D, Lewinsohn D, Scriba T . Polyfunctional CD4 T Cells As Targets for Tuberculosis Vaccination. Front Immunol. 2017; 8:1262. PMC: 5633696. DOI: 10.3389/fimmu.2017.01262. View

14.

Didierlaurent A, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N . Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2016; 16(1):55-63. DOI: 10.1080/14760584.2016.1213632. View

15.

Kwon K, Lee A, Larsen S, Baldwin S, Coler R, Reed S . Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci Rep. 2019; 9(1):15560. PMC: 6820558. DOI: 10.1038/s41598-019-52146-0. View

16.

Yu Q, Wang X, Fan X . A New Adjuvant MTOM Mediates Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2 T Cells. Front Immunol. 2017; 8:585. PMC: 5436497. DOI: 10.3389/fimmu.2017.00585. View

17.

Li J, Zhao A, Tang J, Wang G, Shi Y, Zhan L . Tuberculosis vaccine development: from classic to clinical candidates. Eur J Clin Microbiol Infect Dis. 2020; 39(8):1405-1425. PMC: 7223099. DOI: 10.1007/s10096-020-03843-6. View

18.

Thakur A, Ingvarsson P, Schmidt S, Rose F, Andersen P, Christensen D . Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. Vaccine. 2018; 36(23):3331-3339. DOI: 10.1016/j.vaccine.2018.04.055. View

19.

Amini Y, Tebianian M, Mosavari N, Fasihi Ramandi M, Ebrahimi S, Najminejad H . Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen. Artif Cells Nanomed Biotechnol. 2016; 45(2):291-296. DOI: 10.3109/21691401.2016.1146735. View

20.

Kumarasamy N, Poongulali S, Bollaerts A, Moris P, Beulah F, Ayuk L . A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults. Medicine (Baltimore). 2016; 95(3):e2459. PMC: 4998253. DOI: 10.1097/MD.0000000000002459. View